Coronary Artery Disease

• 

  Publication Venue For

  • Late gadolinium cardiovascular magnetic resonance in the assessment of myocardial viability..  16:365-372. 2005
  • Distinct mouse coronary anatomy and myocardial infarction consequent to ligation..  16:41-44. 2005
  • The role of platelet receptors and adhesion molecules in coronary artery disease..  14:65-79. 2003
  • Measurement of myocardial perfusion by contrast echocardiography: application in the operating room..  11:227-234. 2000
  • Coronary intervention and glycoprotein IIb/IIIa integrin blockade..  10:553-560. 1999
  • Nitric oxide in the cardiovascular system.  10:273-276. 1999
  • Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis..  9:451-456. 1998
  • Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials..  7:732-743. 1996
  • How magnesium therapy may influence clinical outcome in acute myocardial infarction: review of potential mechanisms..  7:364-370. 1996
  • The use of magnesium in the treatment of patients with acute myocardial infarction.  7:339-340. 1996
  • Magnesium in acute myocardial infarction..  6:831-837. 1995
  • Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction..  5:929-936. 1994
  • Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group..  5:611-615. 1994
  • The role of angioplasty after failed thrombolysis for acute myocardial infarction..  5:392-398. 1994
  • The role of angioplasty after successful thrombolysis for acute myocardial infarction..  5:399-406. 1994
  • An analysis of the cause of early mortality after administration of thrombolytic therapy. The Thrombolysis Angioplasty in Myocardial Infarction Study Group..  4:957-964. 1993
  • Baseline characteristics and therapeutic goals in the New Approaches to Coronary Intervention (NACI) registry..  4:1013-1022. 1993
  • Cellular and molecular mechanisms of coronary artery restenosis..  4:254-259. 1993
  • Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty..  4:167-175. 1993
  • Diagnosis and management of ischemic mitral regurgitation with the use of transesophageal echocardiography.  3:377-381. 1992
  • Why are large-scale trials needed?.  3:92-95. 1992
  • Diatrizoate-containing contrast media inhibit platelet aggregation by disrupting fibrinogen binding.  2:389-396. 1991
  • Development of atherosclerotic-like lesions in the sand rat (Psammomys obesus).  1:469-476. 1990
  • Thrombolytic therapy: overview of clinical trials.  1:23-33. 1990
  • Adverse reactions to protamine..  4:420-425. 1993